Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04305587
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
Ticagrelor in Remote Ischemic Preconditioning Study
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Hellenic Society of Interventional Cardiology
- Target Recruit Count
- 245
- Registration Number
- NCT04174261
- Locations
- 🇬🇷
Athens Red Cross Hospital, Athens, Attica, Greece
Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2019-10-29
- Target Recruit Count
- 60
- Registration Number
- NCT04142151
- Locations
- 🇨🇳
Zhenguo Liu, Shanghai, Shanghai, China
Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 26
- Registration Number
- NCT04091074
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2022-03-16
- Target Recruit Count
- 440
- Registration Number
- NCT04088513
- Locations
- 🇨🇳
Longyan First Hospital, Longyan, Fujian, China
🇨🇳The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Region Skane
- Registration Number
- NCT04069234
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 90
- Registration Number
- NCT04006288
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 620
- Registration Number
- NCT03961334
- Locations
- 🇬🇷
Attikon University Hospital, Athens, Greece
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
🇨🇭University Hospital of Basel, Basel, Switzerland
Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets
- Conditions
- Interventions
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Bloodworks
- Target Recruit Count
- 60
- Registration Number
- NCT03787927
- Locations
- 🇺🇸
Bloodworks Northwest Research Institute, Seattle, Washington, United States
Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 61
- Registration Number
- NCT03774394
- Locations
- 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.